Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.

Abstract

Sodium-glucose co-transporter 2 inhibitors, also known as gliflozins, were developed as a novel class of anti-diabetic agents that promote glycosuria through the prevention of glucose reabsorption in the proximal tubule by sodium-glucose co-transporter 2. Beyond the regulation of glucose homeostasis, they resulted as being effective in different clinical trials in patients with heart failure, showing a strong cardio-renal protective effect in diabetic, but also in non-diabetic patients, which highlights the possible existence of other mechanisms through which gliflozins could be exerting their action. So far, different gliflozins have been approved for their therapeutic use in T2DM, heart failure, and diabetic kidney disease in different countries, all of them being diseases that have in common a deregulation of the inflammatory process associated with the pathology, which perpetuates and worsens the disease. This inflammatory deregulation has been observed in many other diseases, which led the scientific community to have a growing interest in the understanding of the biological processes that lead to or control inflammation deregulation in order to be able to identify potential therapeutic targets that could revert this situation and contribute to the amelioration of the disease. In this line, recent studies showed that gliflozins also act as an anti-inflammatory drug, and have been proposed as a useful strategy to treat other diseases linked to inflammation in addition to cardio-renal diseases, such as diabetes, obesity, atherosclerosis, or non-alcoholic fatty liver disease. In this work, we will review recent studies regarding the role of the main sodium-glucose co-transporter 2 inhibitors in the control of inflammation.

• Authors: Sandra Feijóo-Bandín, Alana Aragón-Herrera, Manuel Otero-Santiago, Laura Anido-Varela, Sandra Moraña-Fernández, Estefanía Tarazón, Esther Roselló-Lletí, Manuel Portolés, Oreste Gualillo, José Ramón González-Juanatey, Francisca Lago
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 23 Issue 10 (May 18 2022) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 35628443 (Publication Type: Journal Article, Review)

Chemical References

• Sodium-Glucose Transporter 2
• Sodium-Glucose Transporter 2 Inhibitors
• Sodium
• Glucose

Topics

• Animals
• Diabetes Mellitus, Type 2 (complications, drug therapy)
• Glucose (therapeutic use)
• Heart Failure (drug therapy)
• Humans
• Inflammation (complications, drug therapy)
• Models, Animal
• Sodium
• Sodium-Glucose Transporter 2
• Sodium-Glucose Transporter 2 Inhibitors (pharmacology, therapeutic use)